Advertisement
Takeda Canada Inks Contract With Canadian Blood Services For GLASSIA
(RTTNews) - Takeda Canada Inc., the Canadian arm of Japan's Takeda Pharmaceutical Co. Ltd. (TAK) on Wednesday entered into a contract with Canadian Blood Services (CBS) for GLASSIA (alpha-1 proteinase inhibitor) resulting from CBS's request for proposal for hereditary deficiency of Alpha-1 Antitrypsin Deficiency (Alpha-1).
Glassia has been approved to be listed on the CBS Plasma Protein and Related Products (PPRP) formulary with specific criteria for reimbursement. This marks Takeda's entry into the Alpha-1 community in Canada, building on the company's commitment to developing innovative treatments for rare diseases.
Glassia is a liquid medicine for infusion containing human Alpha 1-Proteinase Inhibitor (A1-PI) also known as alpha-1 antitrypsin (A1AT), which is purified from human blood.
read more
Takeda Says FDA Approves EOHILIA To Treat Eosinophilic Esophagitis
Japan's Takeda Pharmaceutical Co. Ltd. (TAK) announced Monday that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE)1 It will be available in 2 mg/10 mL convenient, single-dose stick packs by the end of February.
RTTNews
|
548 dni temu
Takeda Says Japan Approves CUVITRU Subcutaneous Immunoglobulin For Patients With Agammaglobulinemia
Takeda Pharmaceutical Co. Ltd. (TAK) announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] in patients aged 2 years and older with agammaglobulinemia or hypogammaglobulinemia disorders.
RTTNews
|
688 dni temu
Takeda Says FDA Accepts BLA For ENTYVIO For Maintenance Therapy In Crohn's Disease
Takeda Pharmaceutical Co. Ltd. (TAK) announced Wednesday that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the investigational subcutaneous (SC) administration of ENTYVIO (vedolizumab) for maintenance therapy in adults with moderately to severely active Crohn's disease (CD) after induction therapy with ENTYVIO intravenous (IV).
RTTNews
|
700 dni temu
Takeda Reports Positive Topline Results Of Phase 2b Study Of TAK-279 For Active Psoriatic Arthritis
Takeda Pharmaceutical Co. Ltd. (TAK, TKPHF.PK) announced Monday positive topline results from its randomized, double-blind, placebo-controlled, multiple-dose Phase 2b trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor with next generation selectivity, in people with active psoriatic arthritis.
RTTNews
|
702 dni temu
Australian Market Extends Early Gains In Mid-market
The Australian market is extending early gains in mid-market moves on Thursday, reversing the losses in the previous session, following the broadly positive cues from Wall Street overnight. The benchmark S&P/ASX 200 is moving up to near the 8,900 level to fresh all-time highs, with gains in mining, energy and financial stocks.
RTTNews
|
20 minut temu
Asian Markets Track Wall Street Higher
Asian stock markets are trading mostly higher on Thursday, following the broadly positive cues from Wall Street overnight, on continued optimism over the outlook for interest rates, with the US Fed widely expected to lower rates by a least a quarter point next month. Asian markets closed mostly higher on Wednesday.
RTTNews
|
52 minut temu
Sensex, Nifty Seen Flat To Lower At Open
Indian shares may open flat to slightly lower on Thursday despite mostly positive cues from global markets.
RTTNews
|
1g 12 minut temu
Thai Stock Market May Tick Higher Again On Thursday
The Thai stock market bounced higher again on Wednesday, one session after ending the four-day winning streak in which it had surged almost 50 points or 4.1 percent. The Stock Exchange of Thailand now sits just above the 1,275-point plateau and it may add to its gains from the previous session.
RTTNews
|
1g 51 minut temu
